Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 12:21 PM
October 2025
In this educational session, Stacie Egan, NP, from Ogden Clinic Gastroenterology, explores the critical role of non-invasive testing (NITs) in diagnosing and managing MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction–Associated Steatohepatitis). Stacy explains the key differences between MASLD—fat accumulation without active damage—and MASH, where inflammation and cellular injury drive fibrosis, cirrhosis, and hepatocellular carcinoma. Understanding this distinction is vital for early detection and intervention.
This session also highlights how ALT levels, metabolic comorbidities, and alcohol use should influence decision-making, and why combining test results with clinical context ensures accurate risk stratification. Clinicians will learn how to use NITs not as standalone diagnostics, but as integrated puzzle pieces that drive earlier treatment with lifestyle modification and emerging pharmacotherapies for F2–F3 fibrosis.
Perfect for APPs, NPs, and GIs managing patients with fatty liver disease, this video offers a clear roadmap to detect, monitor, and manage MASH with fibrosis—improving outcomes while minimizing invasive procedures.
Related Podcast
Addressing Health Disparities: Equity Considerations in MASH/MASLD Care
July 2025
In this episode, Patrick Horne, NP at the University of Florida (UF Health), explores the impact of health disparities and socioeconomic inequality on the diagnosis and management of MASH (metabolic-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease). With a focus on rural and underserved populations, Patrick discusses how limited access to quality healthcare, healthy food, exercise options, and non-invasive testing (NITs) like FibroScan or MRI elastography can delay diagnosis and worsen outcomes. He shares practical, empathetic strategies for individualizing care, such as using accessible tools like FIB-4 or APRI, promoting low-cost physical activity like walking or swimming, and providing culturally sensitive nutrition advice tailored to financial and geographic realities. Patrick emphasizes the provider’s role as a patient advocate and coach, helping patients navigate barriers and create sustainable lifestyle modifications. This episode offers key insights for clinicians working to close gaps in care and promote equity in liver disease management.
Watch Now
Common Questions from Community GI About MASH
July 2025
In this practical and timely video, Erin Tanner, NP at Gastro Health in Birmingham, Alabama, shares expert insights on how community gastroenterology providers should approach incidental findings of fatty liver (MASLD/MASH) on abdominal imaging. With over 14 years of experience in GI and hepatology, Erin emphasizes that fatty liver can no longer be ignored, even when discovered during workups for unrelated GI symptoms like reflux or diarrhea. She walks through the step-by-step use of the FIB-4 index to risk-stratify patients and explains when to follow up with further non-invasive testing such as FibroScan® or ultrasound elastography. For patients with F3 fibrosis, Erin outlines next steps including lifestyle interventions, the use of Resmetirom, and the promise of GLP-1 therapies for future treatment. This is a must-watch for GI clinicians aiming to improve outcomes by proactively managing fatty liver disease in everyday practice.
Watch Now
Comparing F3 and F4 Fibrosis With Janet Gripshover
September 2025
Welcome to the MASLD Community Network, where experts share practical insights on diagnosing and managing metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). In this session, Janet Gripshover, NP and Nurse Manager of the Liver Transplant Program at Cedars-Sinai, explores one of the most challenging aspects of hepatology—distinguishing between F3 fibrosis and F4 cirrhosis. She explains why identifying the transition from bridging fibrosis to cirrhosis is critical for patient outcomes, treatment decisions, and cancer surveillance. Using real-world case discussions, Janet reviews non-invasive diagnostic tools such as FIB-4, transient elastography (FibroScan®), ELF testing, and lab findings, highlighting how concordant results strengthen diagnostic confidence. She also addresses risk factors like obesity, type 2 diabetes, hypertension, and sleep apnea, and emphasizes the role of lifestyle modification, GLP-1 therapies, and new treatments that can reduce fat and fibrosis progression. Importantly, she discusses why cirrhosis shifts management priorities from prevention to preservation and underscores the need for hepatocellular carcinoma (HCC) surveillance. Whether you are a hepatology provider, APP, or clinician looking to better understand the nuances of staging MASLD/MASH, this video provides a comprehensive and practical guide to diagnosing and managing advanced liver fibrosis.
Watch Now
Lifestyle Management With Lavinia Iordache
September 2025
In this MASLD Community Network session, Lavinia Iordache uses a real-world case to show how to recognize and manage fatty liver disease with a lifestyle-first approach. She reviews the clinical pathway for at-risk patients (hypertension, dyslipidemia, diabetes, central adiposity), the role of non-invasive tests, and why indeterminate results often require a second modality. The talk clarifies alcohol distinctions and emphasizes that early staging and referral can change prognosis. Practical guidance includes culturally sensitive nutrition counseling (prioritizing the Mediterranean diet), realistic weight-loss targets, and tailored exercise plans—both aerobic and resistance training improve hepatic fat via different pathways. Lavinia also covers behavior strategies and cautions on one-size-fits-all tactics. You’ll leave with a clear, compassionate framework to help patients sustain lifestyle change, optimize cardiometabolic risk, and monitor disease progression over time.
Watch Now
Non-Invasive Testing With Janet Gripshover
July 2025
In this in-depth and practical discussion, Janet Gripshover, NP from Cedars-Sinai in Los Angeles, explores the evolving role of non-invasive testing (NITs) in the diagnosis and risk stratification of MASLD (Metabolic dysfunction-associated steatotic liver disease) and MASH (Metabolic dysfunction-associated steatohepatitis). Drawing from real-world experience and a case study involving a 65-year-old patient with multiple cardiometabolic risk factors, she breaks down the latest 2025 approaches to fibrosis assessment—highlighting the use of FIB-4, ELF score, vibration-controlled transient elastography (FibroScan®), and MR elastography. Gryover also emphasizes how combining tests across modalities can improve accuracy and patient care while avoiding the risks of liver biopsy. Learn how liver stiffness, lab values, and clinical history all intersect to guide care and treatment decisions in patients with fatty liver disease. This session is part of the MASLD/MASH Community Network and is ideal for providers, specialists, and anyone interested in the forefront of liver disease management.
Watch Now
MASLD Basics With Ellie Gonyeau
August 2025
Join Ellie Gonyeau, NP, a GI and hepatology nurse practitioner at Beth Israel Deaconess Medical Center in Boston, for a foundational overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD. Presented through the GHAPP MASLD Community Network and sponsored by Madrigal Pharmaceuticals, this session covers the latest updates in MASLD nomenclature, diagnostic criteria, and non-invasive evaluation strategies. Ellie walks through the 2023 guidelines, emphasizing how MASLD is defined by hepatic steatosis in the presence of at least one metabolic risk factor—such as obesity, type 2 diabetes, hypertension, or dyslipidemia—and the importance of ruling out excessive alcohol use and other causes of chronic liver disease. Using real-world case examples like "JP", Ellie illustrates how to assess disease severity using tools such as FIB-4, FibroScan, and lab workups, while explaining when to consider specialty referral, further imaging, or liver biopsy. The talk also highlights the alarming rates of MASLD in high-risk populations, such as the Latin American community, and explores the disease's potential to silently progress to MASH, fibrosis, or cirrhosis. Whether you're in primary care, GI, or hepatology, this session provides critical insights on early detection, risk stratification, and guideline-based management of this increasingly prevalent condition.
Watch Now
MASLD Pharmacotherapy With Milly Ng
September 2025
Pharmacotherapy for MASLD is rapidly evolving, and clinicians now have more tools than ever to guide treatment decisions. In this session, Milly Ng, NP at Tufts Medical Center in Boston, breaks down a practical framework for when to initiate treatment, how to select the right therapy, and what monitoring strategies to use. From lifestyle modification and statins to GLP-1 receptor agonists and the first FDA-approved liver-directed therapy, resmetirom, this discussion highlights both established and emerging options. You’ll also learn how GLP-1s can support weight loss and liver health, the evidence behind vitamin E and pioglitazone, and the pivotal Maestro NASH trial that secured accelerated approval for resmetirom. Whether you’re managing patients with obesity, diabetes, or advanced fibrosis, this overview offers actionable strategies to simplify complex decisions and improve outcomes in MASLD/MASH care.
Watch Now
Misconceptions About Liver Health
July 2025
In this short and informative video, Miu Lai Ng, a nurse practitioner at Tufts Medical Center, debunks two of the most common myths about liver health. First, she sets the record straight on liver cleanses and detox teas—explaining that your liver already detoxifies your body daily and doesn’t need fad diets or trendy supplements. Instead, what your liver needs is support through sustainable habits like reducing alcohol intake, cutting back on processed sugars, and maintaining a healthy weight. She also highlights a critical point: liver disease is often silent, and many people with significant liver damage have no symptoms until it’s advanced. If you're at risk due to metabolic syndrome, alcohol use, or other factors, Miu Lai urges you to talk to your healthcare provider about screening options like FIB-4 or FibroScan®. Your liver works hard for you—this video is a reminder to return the favor with real, lasting care.
Watch Now
MASLD Pharmacotherapy With Christina Hanson
September 2025
Learn about the latest advances in MASLD and MASH pharmacotherapy in this educational session from the GHAPP MASLD Community Network. Christina Hanson, NP, reviews the evolving landscape of treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH), including the critical role of weight loss, cardiovascular risk reduction, and liver-directed therapies. The discussion covers current management strategies such as GLP-1 receptor agonists, bariatric interventions, statins, and lifestyle modification, while also exploring guideline-supported options like vitamin E and pioglitazone. Special attention is given to the first FDA-approved therapy for MASH, Resmetirom, including its mechanism, clinical trial results, safety considerations, and monitoring recommendations. Whether you are a hepatology specialist, primary care provider, endocrinologist, or advanced practice provider, this session highlights practical approaches to managing patients with MASLD and MASH and offers insights into emerging therapies that may shape future clinical practice.
Watch Now
MASLD Pharmacotherapy With Gabriella McCarty
August 2025
In this presentation, Gabriella McCarty, NP at North Shore Gastroenterology, explores the evolving management of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MASH with a focus on pharmacotherapy. Drawing from her 26 years in gastroenterology, IBD, and hepatology, she explains how fatty liver disease is often detected incidentally and highlights the importance of early diagnosis and patient education. Gabriella reviews the three-pillar approach to treatment—lifestyle and weight loss strategies, cardiovascular risk reduction, and emerging liver-directed therapies. She discusses the role of GLP-1 receptor agonists, Vitamin E, Pioglitazone, and the first FDA-approved therapy, Resmetirom, detailing their mechanisms, benefits, and safety considerations. With insights from the MAESTRO-NASH trial and real-world experience using non-invasive tests like FibroScan, CAP scores, and ELF testing, this session provides practical guidance for clinicians managing MASLD/MASH and preventing disease progression to cirrhosis or hepatocellular carcinoma.
Watch Now